The MSO markup: what comparable managers earn above cost

A management fee has two parts: the cost of the services and the profit on top. The cost side has a benchmark. The profit side usually has a shrug. Ask what markup an MSO should earn and you hear round numbers with no source, which is a problem when the standard is fair market value and the fee is about to be read by an appraiser, a buyer, or a state regulator.

The market has an answer. Across 73 healthcare outsourced-services M&A transactions in the Scope Research Healthcare M&A Valuation Database, 2012 through 2026, the median EBITDA margin is 18.5%. Convert that margin to a markup on cost and you get 22.7%. That is what buyers of non-clinical service businesses have accepted, deal after deal, as the profit those operations earn.

Why M&A comparables are the evidence

The trick to benchmarking MSO profit is that almost no company files financials as "an MSO." But the market is full of companies selling exactly what an MSO sells, one line at a time. Medical billing and revenue cycle firms. Clinical and administrative staffing agencies. Practice consultants. IT and monitoring vendors. Group purchasing organizations. When one gets acquired, its EBITDA margin gets priced by a buyer spending its own money, which beats any survey.

The 73-deal set is built from those transactions: 19 revenue cycle deals, 19 staffing deals, 8 remote monitoring deals, 5 each in consulting and waste management, 4 in IT services, 3 group purchasing organizations, and 10 across other service lines. Together they trace the outsourced non-clinical stack, which is to say the MSO service list.

Margin to markup, the arithmetic

An EBITDA margin is profit over revenue. A markup is profit over cost. Same profit, different denominator, and the conversion is markup = margin / (1 minus margin). It matters because fee opinions are built cost-up, and quoting a margin where a markup belongs understates the fee.

A 15% margin implies a 17.6% markup. The 18.5% median implies 22.7%. A 25% margin implies 33.3%. The markup calculator on the MSOs module does the conversion for any margin, free, and the module filters the comparable set by service line for a fee built on a narrower scope.

What the markup is for

Two checks make a defensible fee. Check one prices the services: non-clinical cost as a share of practice net revenue, median 46.6% across 25 specialties. Check two is this markup. Cost times 1.227 is the market-median fee for that scope. For dermatology, that math supports a fee near 75% of revenue; for lighter scopes it supports far less.

The markup defends the fee in both directions. A fee implying a 40% margin has some explaining ahead of it, since the market's median manager earns 18.5%. And a fee at bare cost fails differently: no rational manager sells at zero margin, so a costless markup reads as something other than a services arrangement. The 22.7% median is the anchor both arguments swing from, which is why it belongs in the FMV work papers and in any quality of earnings review that touches a management fee.

Common questions

What is a typical MSO markup? The median EBITDA margin across 73 healthcare outsourced-services M&A comparables is 18.5%, an implied markup on cost of 22.7%.

How do you convert an EBITDA margin to a markup on cost? Markup = margin / (1 minus margin). An 18.5% margin equals 22.7% of cost. The conversion always makes the markup the larger number.

Where do the comparables come from? The Scope Research Healthcare M&A Valuation Database: 73 priced acquisitions of healthcare outsourced-services companies, 2012 to 2026, spanning revenue cycle, staffing, consulting, monitoring, IT, and group purchasing.

Can an MSO support a markup above 22.7%? Sometimes. Service lines carry different margins, and scope, risk, and capital intensity all move the number. That is an appraiser's call to support, and the module's service-line filters exist for exactly that analysis.

Sources and method

Markup benchmarks are implied by the EBITDA margins of 73 healthcare outsourced-services M&A transactions (2012 to 2026) in the Scope Research Healthcare M&A Valuation Database. Figures cited are the free-tier statistics: the median margin, its implied markup on cost, and the composition of the comparable set. Cost benchmarks referenced are built from public CMS data covering roughly 1.1 million clinicians. Full methodology on the MSOs module.

This article is a market-data benchmarking resource. It does not provide, and must not be relied upon as, a fair market value determination, valuation opinion, appraisal, or legal, tax, or compliance advice. The opinion of value for any specific arrangement remains the professional judgment of a qualified appraiser.